The numbers in this issue are hard to ignore. The OpenAI Foundation pledged at least $1 billion and named life sciences as its first priority. Earendil Labs - a company most of the field is still getting to know - raised $787 million for an AI biologics platform that has generated more than 40 drug programs.

A multi-agent AI system called Cerebra was validated across 3 million patient records from four healthcare systems. And a Technion-led team showed that a deep learning model running on a routine pathology slide can estimate a $3,500 genomic test that guides chemotherapy decisions - published in The Lancet Oncology and validated against one of the largest breast cancer trials ever conducted.

Let’s dive in.